Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-03T00:29:18.874Z Has data issue: false hasContentIssue false
  • English
  • Français

Aripiprazole as Augmentation Treatment of Refractory Generalized Anxiety Disorder and Panic Disorder

Published online by Cambridge University Press:  07 November 2014

Elizabeth A. Hoge ,
John J. Worthington III ,
Rebecca E. Kaufman ,
Hannah R. Delong ,
Mark H. Pollack  and
Naomi M. Simon
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Individuals with anxiety disorders often remain symptomatic despite treatment with a first-line pharmacologic agent. More research examining pharmacotherapy augmentation strategies to improve outcomes is needed.

Methods:

In an 8-week, open-label, prospective augmentation study, we examined the efficacy and tolerability of the novel antipsychotic agent aripiprazole for adult outpatients with generalized anxiety disorder (n=13) or panic disorder (n=10) who remained symptomatic despite treatment for at least 8 weeks with an adequate (or maximally tolerated) dose of typical pharmacotherapy.

Results:

Aripiprazole augmentation was associated with a significant reduction in Clinical Global Impressions-Severity scores (paired t=4.41, df=22, P<.001) in the intent-to-treat sample of 23 individuals. Three subjects (13%) discontinued due to sedation, chest discomfort, and restlessness, respectively.

Conclusion:

These data provide preliminary evidence that aripiprazole may be a useful augmentation strategy for individuals with generalized anxiety disorder or panic disorder who show a limited response to initial pharmacotherapy.

Type
Original Research
Information
CNS Spectrums , Volume 13 , Issue 6 , June 2008 , pp. 522 - 525
Copyright
Copyright © Cambridge University Press 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Faculty Disclosures: Dr. Hoge receives research/grant support from AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Janssen, the National Institutes of Health, Pfizer, Sepracor, and UCB Pharma. Dr. Worthington receives research/grant support from Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Johnson and Johnson, Lichtwer Pharma, Lorex, Novartis, Organon, PamLab, Pfizer, Pharmative, Roche, sanofi-aventis, Sepracor, Solvay, UCB Pharma, and Wyeth; and is on the speaker's bureaus of Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Pfizer, sanofi-aventis, and Wyeth. Mses. Kaufman and Delong do not have an affiliation with or financial interest in any organization that might pose a conflict of interest. Dr. Pollack is an advisor/consultant for AstraZeneca, Brain Cells, Bristol-Myers Squibb, Cephalon, Dov, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Jazz, Medavante, Neurocrine, Neurogen, Novartis, Otsuka, Pfizer, Predix, Roche, sanofi-aventis, Sepracor, Solvay, Tikvah Therapeutics, Transcept, UCB Pharma, and Wyeth; receives research/grant support from AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Janssen, NARSAD, the National Institute on Drug Abuse, the National Institute of Mental Health, Pfizer, Roche, Sepracor, UCB Pharma, and Wyeth; is on the speaker's bureaus of Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Pfizer, Solvay, and Wyeth; and holds equity in Medavante and Mensante. Dr. Simon receives research/grant support from AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Janssen, NARSAD, the National Institute of Mental Health, Pfizer, Sepracor, and UCB Pharma; is on the speaker's bureaus of Eli Lilly, Forest, Janssen, Pfizer, Sepracor, and UCB Pharma; is an advisor for Solvay; and is a consultant to Paramount Biosciences.

Funding/Support: This study was supported by an investigator-initiated Collaborative Research Trial grant from Bristol-Myers Squibb.

Off-label Usage Disclosures: The authors disclose that they will discuss off-label or investigational uses of aripiprazole, olanzapine, quetiapine, and risperidone for the treatment of general anxiety disorder.